印度制药部门在26财政年度增长7-9%,以国内和欧洲需求为主导,尽管美国的增长放缓。 India's pharma sector to grow 7-9% in FY26, led by domestic and European demand, despite slower US growth.

印度制药业预计26财政年度增长7-9%,其动力是国内市场增长8-10%,欧洲增长10-12%,尽管美国市场放缓至3-5%的增长。 India's pharmaceutical industry is projected to grow 7-9% in FY26, driven by 8-10% growth in the domestic market and 10-12% in Europe, despite a slowdown in the US market to 3-5% growth. ICRA 将国内实力归功于扩大的销售队伍、提高的销售代表生产力、农村分销和新产品的推出，并得到救生药物商品及服务税豁免等政府措施的支持。 ICRA attributes domestic strength to expanded sales forces, improved rep productivity, rural distribution, and new product launches, supported by government measures like GST exemptions on lifesaving drugs. 该部门正在将研发支出增加到收入的6%至7%,重点放在特殊和复杂的分子上。 The sector is increasing R&D spending to 6-7% of revenue, focusing on specialty and complex molecules. 预计资本支出将达到42 000至45 000克鲁塞罗,其中25 000克鲁塞罗投资于无机投资。 Capital expenditure is expected to reach ₹42,000–45,000 crore, with ₹25,000 crore in inorganic investments. 由于有利的成本和较高的专业产品份额,预计业务利润率将保持在24-25%的强势。 Operating margins are forecast to remain strong at 24-25% due to favorable costs and higher specialty product shares.